RT Journal Article
T1 The efficacy of three-dimensional conformal radiation therapy on pain and quality of life in patients with painful bone metastases: a prospective study.
A1 Faris, Ayat
A1 Exposito, Jose
A1 Martinez-Unica, Antonio
A1 Arrebola, Juan Pedro
A1 Perez-Carrascosa, Francisco Miguel
A1 Guerrero, Rosario
A1 Tovar, Isabel
K1 Adult
K1 Aged
K1 Aged, 80 and over
K1 Prospective Studies
K1 Quality of Life
K1 Radiotherapy Dosage
AB To evaluate the efficacy of radiation therapy in alleviating pain and improving the quality of life (QoL) with validated questionnaires in patients with painful bone metastases (BoM). This prospective, observational study recruited 167 patients with painful BoM who were treated with palliative radiotherapy (PRT) from February 2015 to February 2018. After the first clinical assessment, the patients filled out specific questionnaires and underwent a fast radiotherapy treatment within 48 hours. The patients were followed up for eight weeks. The median age was 66.30 years. The most common primary cancer was lung cancer (31.1%). The most often prescribed scheme was 8 Gy in one fraction (70%). The patients experienced significant pain response and improved QoL compared with baseline, especially in the first two weeks after radiation. Overall, reduced pain and drug score were reported at two weeks of PRT in 68 (51.5%) and 37 (28%) of patients, respectively. PRT is an effective treatment option for patients with painful BoM.
PB Medicinska Naklada Co.
YR 2020
FD 2020-03-16
LK http://hdl.handle.net/10668/15904
UL http://hdl.handle.net/10668/15904
LA en
NO Faris A, Expósito J, Martínez-Única A, Arrebola JP, Pérez-Carrascosa FM, Guerrero R, et al. The efficacy of three-dimensional conformal radiation therapy on pain and quality of life in patients with painful bone metastases: a prospective study. Croat Med J. 2020 Jul 5;61(3):215-222.
NO The study was supported by Fundación Progreso y Salud and fundación Pública Andaluza para la investigación Biosanitaria Andalucía Oriental (FIBAO).
DS RISalud
RD Apr 12, 2025